Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. (MIST) Stock Overview
Explore Milestone Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
81.8M
P/E Ratio
-3.33
EPS (TTM)
$-0.77
ROE
-1.98%
MIST Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Milestone Pharmaceuticals Inc. (MIST) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 41.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.92.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.33 and a market capitalization of 81.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Joseph G. Oliveto
33
1111 Dr. Frederik-Philips Boulevard, Montreal, QC
2019